Method for treating tardive dyskinesia with Botulinum toxin type B
AssigneeAllergan Sales, Inc.
InventorsK. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
Life of this patent
Estimating the term…
Abstract
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Claims8
A method for treating tardive dyskinesia, the method comprising the step of administering to a human patient an effective amount of botulinum toxin type B in order to treat tardive dyskinesia.
A method for treating tardive dyskinesia, the method comprising the step of administration to a human patient of an effective amount of botulinum toxin type B, the administration of the botulinum toxin type B resulting in an alleviation of a symptom of the tardive dyskinesia within about 1 day to about 3 days and the patient is administered at least about 1,000 units of the botulinum toxin type B.
A method for treating tardive dyskinesia or dystonia the method comprising the step of intramuscular or subcutaneous administration to a human patient of an effective amount of a botulinum toxin type B, the administration of the botulinum toxin type B resulting in an alleviation of a symptom of the tardive dyskinesia or the dystonia within about 1 day to about 3 days, and the patient is administered at least about 1,000 units of the botulinum toxin type B.
A method for treating a condition selected from the group consisting of orofacial dyskinesia, athetosis, dystonia, chorea, tics and facial grimacing by administration to a human patient of an effective amount of a botulinum toxin type B.
Dependencies are inferred from the claim text.